Last reviewed · How we verify

PB 6 doses - Rifampicin, Clofazimine and Dapsone

University of Brasilia · FDA-approved active Small molecule Quality 2/100

PB 6 doses - Rifampicin, Clofazimine and Dapsone is a Small molecule drug developed by University of Brasilia. It is currently FDA-approved. Also known as: PB 6 doses of 3 drugs.

At a glance

Generic namePB 6 doses - Rifampicin, Clofazimine and Dapsone
Also known asPB 6 doses of 3 drugs
SponsorUniversity of Brasilia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PB 6 doses - Rifampicin, Clofazimine and Dapsone

What is PB 6 doses - Rifampicin, Clofazimine and Dapsone?

PB 6 doses - Rifampicin, Clofazimine and Dapsone is a Small molecule drug developed by University of Brasilia.

Who makes PB 6 doses - Rifampicin, Clofazimine and Dapsone?

PB 6 doses - Rifampicin, Clofazimine and Dapsone is developed and marketed by University of Brasilia (see full University of Brasilia pipeline at /company/university-of-brasilia).

Is PB 6 doses - Rifampicin, Clofazimine and Dapsone also known as anything else?

PB 6 doses - Rifampicin, Clofazimine and Dapsone is also known as PB 6 doses of 3 drugs.

What development phase is PB 6 doses - Rifampicin, Clofazimine and Dapsone in?

PB 6 doses - Rifampicin, Clofazimine and Dapsone is FDA-approved (marketed).

Related